Aurinia Pharmaceuticals Inc. (T:AUP*CA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: #140, 14315 - 118 AVENUE
VICTORIA BC T5L 4S6
Tel: N/A
Website: https://www.auriniapharma.com
IR: See website
<
Key People
Daniel G. Billen
Chairman of the Board
Peter S. Greenleaf
President, Chief Executive Officer, Director
Joe Miller
Chief Financial Officer
Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Matthew Donley
Executive Vice President, Operations and Strategy
Scott Habig
Chief Commercial Officer
Greg Keenan
Chief Medical Officer
Michael R. Martin
Chief Business Officer
 
Business Overview
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.
Financial Overview
For the fiscal year ended 31 December 2023, Aurinia Pharmaceuticals Inc revenues increased 31% to $175.5M. Net loss decreased 28% to $78M. Revenues reflect United States segment increase of 54% to $158M. Lower net loss reflects Interest income increase from $5.1M to $17M (income), Corporate, administration and business d decrease of 12% to $75.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.54.
Employees: 300 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $462.81M as of Dec 31, 2023
Annual revenue (TTM): $175.51M as of Dec 31, 2023
EBITDA (TTM): -$80.04M as of Dec 31, 2023
Net annual income (TTM): -$78.02M as of Dec 31, 2023
Free cash flow (TTM): -$34.18M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 144,617,762 as of Feb 14, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.